Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Site News
Market: Market:

Pharmather Hldgs Ltd (PHRM.CN)

Pharmather Hldgs Ltd (PHRM.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO Globe Newswire - Wed May 25, 6:00AM CDT

Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher...

PHRM.CN : 0.140 (unch)
PHRRF : 0.1110 (+0.27%)
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update Globe Newswire - Mon Apr 25, 4:06PM CDT

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product,...

PHRM.CN : 0.140 (unch)
PHRRF : 0.1110 (+0.27%)
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs Globe Newswire - Tue Apr 12, 6:00AM CDT

PharmaTher to file ANDA and 505(b)(2) regulatory submissions with the FDA for novel uses, delivery forms and formulations of ketamine for mental health,...

PHRRF : 0.1110 (+0.27%)
PHRM.CN : 0.140 (unch)
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease Globe Newswire - Wed Mar 23, 6:00AM CDT

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well...

PHRM.CN : 0.140 (unch)
PHRRF : 0.1110 (+0.27%)
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation Globe Newswire - Wed Feb 16, 6:00AM CST

TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1110 (+0.27%)
PHRM.CN : 0.140 (unch)
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus Globe Newswire - Tue Feb 1, 6:00AM CST

Third FDA orphan drug designation for ketamine granted to PharmaTher...

PHRRF : 0.1110 (+0.27%)
PHRM.CN : 0.140 (unch)
Stocks in play: PharmaTher Inc Baystreet - Mon Jan 17, 11:54AM CST

Is pleased to provide an update on the Company’s psilocybin pharmaceutical development programs. The ...

PHRM.CN : 0.140 (unch)
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS Globe Newswire - Wed Jan 12, 6:00AM CST

TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the...

PHRRF : 0.1110 (+0.27%)
PHRM.CN : 0.140 (unch)
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022 Globe Newswire - Tue Dec 21, 2021

Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products Expected milestones for 2022...

PHRM.CN : 0.140 (unch)
PHRRF : 0.1110 (+0.27%)
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio Globe Newswire - Tue Nov 30, 2021

TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage...

PHRRF : 0.1110 (+0.27%)
PHRM.CN : 0.140 (unch)

Barchart Exclusives

We’ve Got to Get Real: The Market is Significantly Overvalued Barchart - 1 hour ago
As much as analysts insist we’re the best house in the worst block, the equities sector is historically overvalued and requires a correction. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' : 'America/Chicago' ]] CDT
Reserve Your Spot